Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Final results for phase II study of R-1549 in gastric cancer

Nov. 10, 2003

Actimid enters phase II trial for prostate cancer

Nov. 3, 2003

Anti-EGFR antibody with ADCC-inducing activity

Oct. 31, 2003

Favrille raises financing to support phase II and III trials of FavId for NHL

Oct. 21, 2003

ACP-2127 advanced into preclinical testing

Oct. 20, 2003

Signal patent describes novel ER modulators for osteoporosis, cancer, etc.

Oct. 16, 2003

Evidence of antitumor activity for Xcellerated T-cells and IL-2 in renal cell carcinoma

Oct. 9, 2003

NeuTec seeks development partners for Mycograb for cancer

Oct. 8, 2003

Expansion of phase III Virulizin trial

Oct. 2, 2003

Telomerase-targeting vaccines in development at GemVax

Oct. 1, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...